Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs AST 008 (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Exicure
  • Most Recent Events

    • 26 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 25 Sep 2018 Status changed from planning to not yet recruiting.
    • 20 Sep 2018 According to an Exicure media release, the company expects to initiate this trial before year end and anticipates preliminary data from the Phase 1b stage in late 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top